Matthieu Schapira - Toxicology

Author Information

Matthieu Schapira is a researcher affiliated with the Structural Genomics Consortium and the Department of Pharmacology and Toxicology at the University of Toronto, located in Canada. His work primarily focuses on the field of structural genomics and pharmacology, contributing significantly to the understanding of the human proteome and the development of chemical probes and drugs.

Research Contributions

Matthieu Schapira has made substantial contributions to the field of pharmacology and toxicology, with a particular emphasis on structural genomics. His recent research includes the study of epigenetic chemical probes and their off-target effects, the discovery of small molecule antagonists, and the development of computational methods for hit-finding in drug discovery. Notably, he has also worked on the structural and mechanistic analysis of the SARS-CoV-2 NSP13 helicase, which is crucial in the context of the COVID-19 pandemic.

Aliases

Matthieu Schapira is also known by the aliases M Schapira and M. Schapira. These variations of his name may appear in different publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	12,891
H-index	53
Paper Count	282

Publications:

A combinatorial anticancer drug screen identifies off-target effects of epigenetic chemical probes

DOI: 10.1101/2022.04.14.488411

Year: 2022

Target 2035 – update on the quest for a probe for every protein

DOI: 10.1039/d1md00228g

Year: 2022

CACHE (Critical Assessment of Computational Hit-finding Experiments): A public–private partnership benchmarking initiative to enable the development of computational methods for hit-finding

DOI: 10.1038/s41570-022-00363-z

Year: 2022

Discovery of small molecule antagonists of human Retinoblastoma Binding Protein 4 (RBBP4)

DOI: 10.1101/2022.01.05.475077

Year: 2022

Structure-Based Survey of the Human Proteome for Opportunities in Proximity Pharmacology

DOI: 10.1101/2022.01.13.475779

Year: 2022

Pharmacological targeting of a PWWP domain demonstrates cooperative control of NSD2 localization

DOI: 10.1101/2021.03.05.433782

Year: 2021

Correction to "Structure-Activity Relationship of USP5 Inhibitors".

DOI: 10.1021/acs.jmedchem.1c02118

Year: 2021

Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase

DOI: 10.1038/s41467-021-25166-6

Year: 2021

Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with 4-(4-(4-(3,4-difluoro-phenyl)-piperidin-1-ylsulfonyl)-phenyl)-4-oxo-butanoic acid

DOI: 10.2210/PDB7MS5/PDB

Year: 2021

Structure of USP5 zinc-finger ubiquitin binding domain co-crystallized with (2-fluoro-4-((4-phenylpiperidin-1-yl)sulfonyl)benzoyl)glycine

DOI: 10.2210/PDB7MS6/PDB

Year: 2021

What Are the Future Directions in Trace Element Research?

How Do TLVs Differ from Other Exposure Limits?

Why is In Silico Modeling Important in Toxicology?

What is the Importance of Public Awareness?

How Does Synthetic Biology Relate to Toxicology?

What are the Benefits of Passive Immunity in Toxicology?

What is a Safety Rating Scale?

What is the Significance of Toxicodynamics in Risk Assessment?

How Are Toxicological Risks Assessed?

What are the Challenges in Pharmacovigilance?

Partnered Content Networks

Relevant Topics